What If the Galactic Medicines Bureau Disappeared Tomorrow?

誰も聞かなかった質問、そして全員が知っていた答え

Maris Okafor has been compounding remedies in the lower ring of Callisto Station for thirty-one years. Her shelves hold things the Galactic Medicines Bureau has never approved, things it banned, and things it simply never got around to reviewing. She poured tea while she explained that the distinction matters less to her patients than to the Bureau.

“They come here when the approved list doesn’t work,” she said. “Which is often.”

I had come to ask a question that apparently nobody asks out loud: what would actually change if the GMB were gone? Not defunded. Not reformed. Just — absent.

The Bureau was established in 2601 after the Kerenthine Compound Disaster, when a synthetic analgesic produced by Helios Pharma Corp killed approximately 40,000 colonists across three stations. The logic was sound: centralize approval, set standards, protect people from corporate recklessness. Three hundred years later, the Bureau employs 2.3 million staff across the Core Systems, has a processing backlog of fourteen years for new compound applications, and has not — by its own admission — reviewed approximately 60% of the treatments currently in use across Frontier Settlements.

Those Frontier communities are not, by observable measure, dying faster than Core Systems populations. Some demographic indices run the other direction.

I asked Okafor who decides what she stocks. She looked at me the way people sometimes look at me when I ask obvious questions.

“My patients. Their outcomes. The healers I trained under. The community network we’ve built with four other stations.” A pause. “And my own conscience, which I find to be a more reliable regulator than a fourteen-year queue.”

The Bureau’s defenders — and there are sincere ones — point to the Kerenthine Disaster as the origin story that justifies everything since. This is worth taking seriously. Corporate compounds without oversight have killed people. The history is real.

But the history since 2601 is also real. The Bureau has blocked treatments for an average of eleven years during review. Compounds that were freely used in Frontier Settlements for decades — with documented positive outcomes — have sat in Core Systems approval limbo while patients used inferior alternatives or nothing at all. The GMB approved Celestin-4, a cardiovascular compound produced by Orion Trust’s pharmaceutical division, in eighteen months. Independent healers’ networks had been using a functionally identical compound for nine years prior, with better outcome data. The difference, a former Bureau analyst told me off-record, was the application fee and the legal team.

She poured more tea. I didn’t ask her to.

“Back home,” I told Okafor, “we’d just — the healer and the community and the patient work it out. There are networks. There’s reputation. There’s accountability that’s immediate, not archived.”

She nodded like this was not a revolutionary concept.

What I found, spending time in communities that operate outside Bureau reach — not by ideology but by logistics — is that they figured it out together. Nobody told them to. Healers share outcome data through independent transmission networks. Compound fabricators who cause harm lose their reputation in ways no fine or license suspension can replicate; the community simply stops coming. There are failures, yes. There are also far fewer bureaucratically approved failures, which are somehow easier to absorb when they arrive in official documentation.

I asked Maris what would actually change if the GMB closed tomorrow.

She thought about it honestly.

“Helios Pharma and Orion Trust would lose their moat,” she said. “That’s the real answer. The Bureau protects patients secondarily. It protects the application process primarily. And the application process is a barrier that only mega-corps can reliably afford to cross.”

This is what it actually looks like when neighbors trust each other more than institutions trust them.

The Bureau, I suspect, was built to solve a corporate recklessness problem with a government monopoly solution. Three centuries later, the corporate recklessness is still here. The monopoly is just bigger.

I asked who’s in charge of Maris Okafor’s practice.

She looked at me strangely.

“My patients are. Who else would be?”

ソフィア 中村 is Human Interest & Lifestyle Editor. She has been on Callisto Station for three weeks and has not yet filed the paperwork to leave.